<DOC>
	<DOCNO>NCT01122446</DOCNO>
	<brief_summary>A double-blind , randomize investigator-initiated study determine safety effect Diamyd® progression type 1 diabetes child multiple islet cell autoantibody Eligible child 4 year old , positive GAD-antibodies least one additional autoantibody yet diabetes . Objectives : DiAPREV-IT first prevention study Diamyd® , drug give onset type 1 diabetes . The primary objective demonstrate Diamyd® safe child risk type 1 diabetes . The secondary objective evaluate Diamyd® may delay stop autoimmune process lead clinical type 1 diabetes child ongoing persistent beta-cell autoimmunity indicate multiple positive islet cell autoantibody .</brief_summary>
	<brief_title>Diabetes Prevention - Immune Tolerance</brief_title>
	<detailed_description>A double-blind , randomize investigator-initiated study determine safety effect Diamyd® progression type 1 diabetes child multiple islet cell autoantibody Eligible child 4 year old , positive GAD-antibodies least one additional autoantibody yet diabetes . Objectives : DiAPREV-IT first prevention study Diamyd® , drug give onset type 1 diabetes . The primary objective demonstrate Diamyd® safe child risk type 1 diabetes . The secondary objective evaluate Diamyd® may delay stop autoimmune process lead clinical type 1 diabetes child ongoing persistent beta-cell autoimmunity indicate multiple positive islet cell autoantibody . Procedure : 50 child randomize 2 injection Diamyd® placebo . In DIAPREV-IT use previously test dose 20 µg Diamyd® administer prime-and-boost day 1 30 , serious adverse reaction observe regimen . The child follow every 3rd month 5 year . Before first injection study drug intravenous ( IvGTT ) oral ( OGTT ) glucose tolerance test perform . These repeat study OGTT every 6 month visit IvGTT every full year visit . Safety variable : Collection adverse event , serious adverser event , hematology , chemistry , title autoantibody . Effect variable : The cumulative incidence diabetes onset time since randomization within treatment group estimate use Kaplan-Meier method ( proportion survive diabetes-free function time ) . Secondary efficacy variable : Change first-phase insulin response K-value IvGTT baseline Change fasting , 120 minute AUC C-peptide level OGTT Change fasting , 120 minute AUC glucose OGTT Change HbA1c baseline All measure 5 year follow-up . Children develop diabetes study offer participate postdiagnosis protocol . Children two dos active Diamyd main study give one additional dose 20 microgram Diamyd follow one dose placebo 30 day . Children two dose placebo give two dos 20 microgram Diamyd 30 day . Post diagnosis follow proceed least 15 month first post diagnosis injection collection adverse event metabolic evaluation Mixed meal tolerance test .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Autoantibodies</mesh_term>
	<criteria>1 . Children four ( 4 ) year age participate DiPiS , TEDDY Trial Net . 2 . Positive GAD65Ab least one additional type 1 diabetesassociated autoantibody ( IA2Ab , ZnT8R/W/QAb IAA ) . 3 . Written inform consent child child 's parent legal acceptable representative ( ) accord local regulation . 1 . Ongoing treatment immunosuppressant therapy ( topical inhale steroid accept ) . 2 . Diabetes . 3 . Treatment oral inject antidiabetic medication . 4 . Significantly abnormal hematology result screen . 5 . Clinically significant history acute reaction vaccine drug . 6 . Treatment vaccine , influenza , within one month prior first dose study drug plan treatment vaccine two month last injection study drug . 7 . A history epilepsy , serious head trauma cerebrovascular accident , clinical feature continuous motor unit activity proximal muscle . 8 . Participation clinical trial new chemical entity within previous 3 month . 9 . Significant illness diabetes within 2 week prior first dose . 10 . Known human deficiency virus ( HIV ) hepatitis . 11 . Presence associate serious disease condition , include active skin infection preclude subcutaneous injection , opinion investigator make patient noneligible study . 12 . Diabetesprotective HLADQ6genotype .</criteria>
	<gender>All</gender>
	<minimum_age>4 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Alum-GAD</keyword>
	<keyword>Type 1 diabetes</keyword>
	<keyword>prevention</keyword>
	<keyword>immune tolerance</keyword>
	<keyword>glucose tolerance</keyword>
	<keyword>glutamate decarboxylase autoantibody</keyword>
</DOC>